title: [Treatment of hepatitis C].
abstract: Hepatitis C treatment has made a lot of progress in the last two decades. Treatment with pegylated interferon and ribarin is associated with sustained virological response in more than 50% of patients. This improvement is due in one part to the adaptation of treatment dose and duration according to genotype, liver fibrosis and response-guided therapy, fibrosis in another part to a better pretreatment management of co-morbidities and a better prevention and management of side effects. New direct antiviral agents will become soon available and will lead to an improvement of sustained virological response with maybe more complex therapy leading to a new management of patients.
authors: Service d'hépato-gastroentérologie, hôpital Saint-Joseph, 13008 Marseille, France. mbourliere@hopital-saint-joseph.fr
authors: Marc
authors: M
authors: Bourlière
authors: Asma
authors: A
authors: Khaloun
authors: Paul
authors: P
authors: Castellani
authors: Isabelle
authors: I
authors: Portal
authors: Christelle
authors: C
authors: Ansaldi
authors: Xavier
authors: X
authors: Adhoute
authors: Stanislas
authors: S
authors: Pol
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins